6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection

US9266904B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Lei Guo · Kowloon, CN
• Taishan Hu · Shanghai, CN
• Yimin Hu · Shanghai, CN
• Buelent Kocer · Basel, CH
• Buyu Kou · Shanghai, CN
• Gangqin Li · Shanghai, CN
• Xianfeng Lin · Shanghai, CN
• Haixia Liu · Shanghai, CN
• Hong Shen · Shanghai, CN
• Houguang Shi · Shanghai, CN
• Guolong Wu · Shanghai, CN
• Zhisen Zhang · Shanghai, CN
• Mingwei Zhou · Shanghai, CN
• Wei Zhu · Shanghai, CN

Key dates

• Filing date: May 16, 2014
• Grant date: Feb 23, 2016
• Expiry date: Aug 6, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/506
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides novel compounds having the general formula:wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as or pharmaceutically acceptable salts, or tautomerism isomers, or enantiomers, or diastereomers thereof. The invention also contains compositions including the compounds and methods of using the compounds.